Literature DB >> 7493291

Precore and X region mutants in hepatitis B virus infections among renal dialysis patients.

M A Feitelson1, L X Duan, J Guo, N Horiike, G McIntyre, B S Blumberg, H C Thomas, W Carman.   

Abstract

Hepatitis B virus (HBV) variants containing mutations within the X and the precore regions of the viral genome were demonstrated by polymerase chain reaction (PCR) amplification and DNA sequencing in renal dialysis patients with different serological patterns of HBV infection. Among carriers, X region deletion mutants predominated in patients who lost hepatitis B e antigen (HBeAg), or developed anti-HBe, but not in persistently HBeAg-positive patients. The precore region remained wild type in all carriers whether or not they seroconverted from HBeAg to anti-HBe. The frequency of precore and X region mutants was greatest among non-carrier patients with viral antibodies as the only indication of infection and among patients with non-A, non-B hepatitis (NANBH), suggesting an inverse relationship between the presence of wild type HBV markers and the presence of HBV mutants. Furthermore, the detection of one but not the other mutation in many serum samples suggests that these mutations are independently selected for during infection. Finally, the absence of HBV DNA in 21 'uninfected' dialysis patients with normal transaminases and no viral serology, suggests that replication of these mutants is associated with hepatitis. These results have important implications for HBV screening and treatment, as well as for the pathogenesis of chronic infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493291     DOI: 10.1111/j.1365-2893.1995.tb00068.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  1 in total

1.  Use of PCR in resolving diagnostic difficulties potentially caused by genetic variation of hepatitis B virus.

Authors:  F J van Deursen; K Hino; D Wyatt; P Molyneaux; P Yates; L A Wallace; B C Dow; W F Carman
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.